Publications

Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia.

Author(s): McMaster ML,  Berndt SI,  Zhang J,  Slager SL,  Li SA,  Vajdic CM,  Smedby KE,  Yan H,  Birmann BM,  Brown EE,  Smith A,  Kleinstern G,  Fansler MM,  Mayr C,  Zhu B,  Chung CC,  Park JH,  Burdette L,  Hicks BD,  Hutchinson A,  Teras LR,  Adami HO,  Bracci PM,  McKay J,  Monnereau A,  Link BK,  Vermeulen RCH,  Ansell SM,  Maria A,  Diver WR,  Melbye M,  Ojesina AI,  Kraft P,  Boffetta P,  Clavel J,  Giovannucci E,  Besson CM,  Canzian F,  Travis RC,  Vineis P,  Weiderpass E,  Montalvan R,  Wang Z,  Yeager M,  Becker N,  Benavente Y,  Brennan P,  Foretova L,  Maynadie M,  Nieters A,  de Sanjose S,  Staines A,  Conde L,  Riby J,  Glimelius B,  Hjalgrim H,  Pradhan N,  Feldman AL,  Novak AJ,  Lawrence C,  Bassig BA,  Lan Q,  Zheng T,  North KE,  Tinker LF,  Cozen W,  Severson RK,  Hofmann JN,  Zhang Y,  Jackson RD,  Morton LM,  Purdue MP,  Chatterjee N,  Offit K,  Cerhan JR,  Chanock SJ,  Rothman N,  Vijai J,  Goldin LR,  Skibola CF,  Caporaso NE

Journal: Nat Commun

Date: 2018 Oct 10

Major Program(s) or Research Group(s): PLCO

PubMed ID: 30305637

PMC ID: PMC6180091

Abstract: Waldenström macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL) is a rare, chronic B-cell lymphoma with high heritability. We conduct a two-stage genome-wide association study of WM/LPL in 530 unrelated cases and 4362 controls of European ancestry and identify two high-risk loci associated with WM/LPL at 6p25.3 (rs116446171, near EXOC2 and IRF4; OR = 21.14, 95% CI: 14.40-31.03, P = 1.36 × 10-54) and 14q32.13 (rs117410836, near TCL1; OR = 4.90, 95% CI: 3.45-6.96, P = 8.75 × 10-19). Both risk alleles are observed at a low frequency among controls (~2-3%) and occur in excess in affected cases within families. In silico data suggest that rs116446171 may have functional importance, and in functional studies, we demonstrate increased reporter transcription and proliferation in cells transduced with the 6p25.3 risk allele. Although further studies are needed to fully elucidate underlying biological mechanisms, together these loci explain 4% of the familial risk and provide insights into genetic susceptibility to this malignancy.